TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 11.35
+0.05 (0.44%)
Mar 24, 2026, 1:30 PM CST
TPEX:4157 Revenue
In the year 2025, TaiGen Biopharmaceuticals Holdings had annual revenue of 259.47M TWD with 72.24% growth. TaiGen Biopharmaceuticals Holdings had revenue of 231.22M in the quarter ending December 31, 2025, with 2,104.37% growth.
Revenue
259.47M
Revenue Growth
+72.24%
P/S Ratio
31.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 259.47M | 108.82M | 72.24% |
| Dec 31, 2024 | 150.65M | 27.52M | 22.35% |
| Dec 31, 2023 | 123.13M | 86.90M | 239.87% |
| Dec 31, 2022 | 36.23M | -1.26B | -97.20% |
| Dec 31, 2021 | 1.29B | 1.27B | 5,426.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Savior Lifetec | 1.20B |
| Adimmune | 1.20B |
| PharmaEngine | 911.42M |
| Mycenax Biotech | 740.24M |
| TCM Biotech International | 685.49M |
| Tanvex BioPharma | 400.97M |
| Gongwin Biopharm Holdings | 36.45M |